SF-1019: Other Areas of Potential Impact
We believe that SF-1019 can be used
to “scavenge and kill” metastasis cells
in patients undergoing chemotherapy
It is possible that SF-1019 and/or ICPF may eventually be used as:
A replacement for the use of antibiotics as the therapy of choice for infectious diseases thus reducing usage of antibiotics and decreasing pressure that drives the development of antibiotic resistant bacterial strains.
A new and affordable therapy for serious infectious diseases that devastate the third world developing countries such as cholera, dysentery, and tuberculosis.
A “prophylactic” for short term protection in a bio-terrorism arena or other contagion environs.
A “prophylactic” to patients undergoing major surgery to prevent post-operative infection.
To provide “long term” protection as a vaccine adjuvant.
A safe and effective therapeutic for the prevention and treatment of seasonal influenza outbreaks.
As an adjunctive with other agents for the treatment of drug resistant infections.
To “scavenge and kill” metastasis cells in patients undergoing chemotherapy or surgery for the treatment of neo-plastic disease as demonstrated in clinical tests where ICPF prevented tumorogenesis in melanoma challenged models, Ohio University, Mississippi State University, University of Mississippi and Louisiana State University.
Presently being explored for therapeutic affect against current strains of Avian Flu.
Argyll Biotechnologies believes that SF-1019 comprises new classes of lipo-peptides that are potent anti-inflammatory agents, immunoregulators and Immune Cell Potentiating Factors (ICPF). Pre-clinical human studies, animal studies and laboratory data demonstrate a wide range of potential prophylactic and therapeutic applications. It is believed that SF-1019 is a readily available platform technology that will spawn further research and additional benefits to the human condition.
Argyll Biotechnologies has initiated the approval process in several countries. The company will continue its efforts to pursue regulatory approval for SF-1019 with the compassionate goal that it may become a first line defense to mainstream medical practitioners. Argyll Biotechnologies has transferred its world-wide rights to market and distribute SF-1019 to Immunosyn Corporation by way of an exclusive licensing agreement.
